Company’s selection of eosinophilic esophagitis for its lead indication to usher in a new era for allergic and autoimmune disease PASADENA, Calif., December 18, 2024--(BUSINESS WIRE)--Holoclara, a ...
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve ...
PASADENA, Calif.--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback